This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vokes, E. E. Search for Related Content PubMed PubMed Citation Articles by Vokes, E. E.

Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Non-Small Cell Lung Cancer

Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois, USA

Correspondence: Everett E. Vokes, M.D., Director, Section of Hematology/Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, Illinois 60637-1470, USA. Telephone: 773-702-9306; Fax: 773-702-3002; e-mail: evokes{at}medicine.bsd.uchicago.edu

Multiple concepts of combined modality therapy for locoregionally advanced inoperable non-small cell lung cancer have been investigated. These include induction chemotherapy, concomitant chemoradiotherapy, and intensified radiation therapy schedules. To date, induction chemotherapy has been validated in randomized prospective trials versus radiotherapy alone. Concomitant chemoradiotherapy has led to promising results when combination chemotherapy regimens were used in the phase II setting. In addition, concomitant chemoradiotherapy has been shown to be superior to induction chemotherapy in direct comparison. Finally, accelerated radiotherapy has been shown to lead to improved locoregional control and survival in one randomized study. Based on these observations, the Cancer and Leukemia Group B (CALGB study 9431) investigated the addition of either vinorelbine, paclitaxel, or gemcitabine to cisplatin. In this trial, patients with locally advanced and inoperable non-small cell lung cancer received two cycles of induction chemotherapy with an additional two cycles of concomitant chemoradiotherapy utilizing the same agents accompanied by standard radiation to a total dose of 66 Gy. One hundred eighty-seven patients were entered on this study. An early analysis showed the median survival time was 17 months for all patients entered on the trial. In the context of other CALGB studies, the data from this trial are encouraging, and the regimens used warrant further study.

Key Words. Non-small cell lung cancer • Concomitant chemoradiotherapy • Induction chemotherapy • Radiation therapy

This article has been cited by other articles:

				C. P. Belani, H. Choy, P. Bonomi, C. Scott, P. Travis, J. Haluschak, and W. J. Curran Jr Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol J. Clin. Oncol., September 1, 2005; 23(25): 5883 - 5891. [Abstract] [Full Text] [PDF]

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				M. J. Edelman New Directions in the Treatment of Non-Small Cell Lung Cancer: An Overview Oncologist, February 1, 2001; 6(2008): 1 - 3. [Abstract] [Full Text] [PDF]